Encompass Health Corp’s filing revealed that its Chief Accounting Officer Price Andrew L unloaded Company’s shares for reported $0.5 million on Feb 13 ’25. In the deal valued at $98.29 per share,5,042 shares were sold. As a result of this transaction, Price Andrew L now holds 69,164 shares worth roughly $6.81 million.
Then, COLTHARP DOUGLAS E sold 12,260 shares, generating $1,058,474 in total proceeds. Upon selling the shares at $86.34, the EVP & Chief Financial Officer now owns 136,227 shares.
Before that, Douglas Coltharp bought 12,260 shares. Encompass Health Corp shares valued at $1,058,520 were divested by the Officer at a price of $86.34 per share.
KeyBanc Capital Markets initiated its Encompass Health Corp [EHC] rating to an Overweight in a research note published on October 11, 2024; the price target was $115. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. Barclays began covering EHC with “an Overweight” recommendation on March 06, 2024. Barclays started covering the stock on March 14, 2023. It rated EHC as “an Equal weight”.
Price Performance Review of EHC
On Tuesday, Encompass Health Corp [NYSE:EHC] saw its stock fall -1.34% to $98.45. Over the last five days, the stock has lost -2.17%. Encompass Health Corp shares have risen nearly 6.61% since the year began. Nevertheless, the stocks have risen 32.33% over the past one year. While a 52-week high of $104.55 was reached on 02/07/25, a 52-week low of $74.27 was recorded on 01/03/25. SMA at 50 days reached $96.55, while 200 days put it at $93.29.
Levels Of Support And Resistance For EHC Stock
The 24-hour chart illustrates a support level at 97.58, which if violated will result in even more drops to 96.71. On the upside, there is a resistance level at 99.33. A further resistance level may holdings at 100.21. The Relative Strength Index (RSI) on the 14-day chart is 48.48, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.42%. Stochastics %K at 52.65% indicates the stock is a holding.
The most recent change occurred on September 24, 2021 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $98 price target.
